Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valsartan/hydrochlorothiazide.

H D Langtry1, K J McClellan

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|June 3, 1999
PubMed
Summary
This summary is machine-generated.

Valsartan/hydrochlorothiazide (HCTZ) effectively lowers blood pressure, showing greater efficacy than monotherapy or increased valsartan dosage. This combination therapy for hypertension is well-tolerated and maintains effectiveness long-term.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quantum critical fluctuations in the heavy fermion compound Ce(Ni0.935Pd0.065)₂Ge₂.

Journal of physics. Condensed matter : an Institute of Physics journal·2014
Same author

Anisotropic thermal conductivity in uranium dioxide.

Nature communications·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hypertension Management

Background:

  • Essential hypertension is a widespread condition requiring effective therapeutic strategies.
  • Valsartan, an angiotensin II AT1 receptor blocker, and hydrochlorothiazide (HCTZ), a thiazide diuretic, are established antihypertensive agents.
  • Combination therapy is often employed to achieve synergistic blood pressure reduction.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of combining valsartan and HCTZ for essential hypertension.
  • To compare the combination therapy's effectiveness against monotherapy and dose escalation of valsartan.
  • To assess the long-term maintenance of blood pressure control and safety profile.

Main Methods:

  • Clinical trials involving patients with essential hypertension.

Related Experiment Videos

  • Administration of valsartan/HCTZ combination therapy at varying dosages (e.g., 80 mg/day valsartan with 12.5 or 25 mg/day HCTZ).
  • Comparison of treatment arms included valsartan monotherapy dose escalation and placebo.

    • Main Results:

    • Valsartan/HCTZ demonstrated additive blood pressure reductions compared to monotherapy.
    • Combination therapy yielded greater blood pressure reduction than increasing valsartan dosage alone.
    • The combination was well-tolerated, with adverse event rates similar to placebo; HCTZ-induced hypokalemia was less frequent.

    Conclusions:

    • Valsartan/HCTZ is a highly effective and well-tolerated treatment for essential hypertension.
    • The combination offers superior blood pressure control compared to escalating valsartan dose or monotherapy.
    • Sustained efficacy and favorable safety profile support the long-term use of valsartan/HCTZ.